Blog

IS devices can generally be categorized as which of the following? I.    Pressure-oriented II.  Flow-oriented III. Volume-oriented

  Which of the following modes of lung expansion therapy is physiologically most normal?

The patient is a 32-year-old female who presents to the clinic with worsening left buttock pain. On exam, lumbar AROM with overpressure is within normal limits and non-painful. Repeated motions do not change the patient’s symptoms and the slump and straight leg raise tests are negative. Hip AROM and PROM is WNL in all directions and FADDIR is negative. The therapist then performs the test in the attached video and finds it to be negative on the right and reproduces the patient’s concordant pain on the left. Which of the following is the next BEST decision the therapist should make?

Which of the following should be considered when selecting a bronchial hygiene strategy? Patient’s goals, motivation, and preferences Effectiveness and limitations of technique or method Patient’s age, ability to learn, tendency to fatigue Need for assistants, equipment, and cost

A 48-year-old male has chronic LBP for 2 years. He believes his spine is “fragile,” avoids exercise, and has no red flags. Which key pain neuroscience education message should be emphasized?

A 75-year-old man comes to your clinic with complaints of right hip pain and dysfunction. He notes that this has been coming on for some time, but has worsened significantly over the past 6 weeks. He notes he seems to be losing strength in his right leg. He reports mild numbness at his big toe. He is an avid hunter, but is now unable to climb trees to get to his tree stand. The patient’s referral from the sports MD gave a diagnosis of hip arthritis due to imaging findings of mild joint space loss. You don’t feel that this is likely and want to rule out this diagnosis. Tests with high______are used for screening purposes because a negative test would rule____this pathology.

Your patient is a 64-year-old female with two weeks of low back pain and difficulty bending over to get dressed in the morning. Her motion is limited actively with pain at end-range, and her accessories are hypomobile and painful in all directions but feel better with repeated. Based on these findings, the MOST appropriate intervention to address her decreased ability to get dressed in the morning is:

You are evaluating a 74-year-old patient for chronic low back pain and bilateral leg pain (right > left) that is worse with walking. As part of a thorough, broad to narrow examination you perform history, systems review, and tests and measures. In systems review, you identify a directional preference for flexion as the patient notes an improvement in leg pain with repeated lumbar flexion. The patient has a positive slump and SLR bilaterally. When you get to special tests at the end of your exam, you select to perform prone instability test, thigh thrust test, and Well’s straight leg raise test. Prone instability is positive, Well’s SLR is negative, and thigh thrust is positive. Based on the above information, the MOST likely diagnosis is:

When conducting an interview on a 35 year old white male, the nurse performs a FICA Assessment.  What kind of information is the nurse gathering data about when using this tool?

Please read this abstract from a clinical trial:  Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC) Background: To compare the efficacy and safety of CAPIRI+bevacizumab (Bev) in comparison with FOLFIRI+Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC). Methods: Patients were randomised to receive either FOLFIRI plus Bev 5 mg/kg every 2 weeks (Arm-A) or CAPIRI plus Bev 7.5 mg/kg every 3 weeks (Arm-B). Results: Three hundred thirty-three patients (Arm-A=167; Arm-B=166) were enrolled into the study. No difference was observed in median progression-free survival (PFS) (10.0 and 8.9 months; P=0.64), overall survival (25.7 and 27.5 months; P=0.55) or response rates (45.5 and 39.7%; P=0.32) for FOLFIRI-Bev and CAPIRI-Bev, respectively. Patients treated with CAPIRI-Bev presented significantly higher incidence of diarrhoea (P=0.005), febrile neutropenia (P=0.003) and hand-foot skin reactions (P=0.02) compared with patients treated with FOLFIRI-Bev. Treatment delays (P=0.05), dose reduction (P